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Interleukin-13 is a cytokine important for develop-
ment of T helper cell type 2 (Th2) responses and plays
a critical role in asthma and allergy. The IL-13
Receptor a2 (IL-13Ra2) is a receptor for IL-13 lacking
canonical Jak/STAT signaling functions. Here we
present the crystal structure along with a mutational
and biophysical analysis of the IL-13/IL-13Ra2
complex. While retaining a similar mode of IL-13
binding to its related signaling receptor, IL-13Ra1,
IL-13Ra2 uses peripheral receptor residues unused
in the IL-13/IL-13Ra1 complex to generate a larger
and more complementary interface for IL-13. This
results in a four orders of magnitude increase in
affinity, to the femtomolar level, compared to
IL-13Ra1. Alanine scanning mutagenesis of the
IL-13 interface reveals several common ‘‘hotspot’’
residues important for binding to both receptors,
but also identifies a prominent IL-13Ra2-specific
contact. These results provide a framework for devel-
opment of receptor subtype-selective IL-13 antago-
nists and indicate a decoy function for IL-13Ra2.
INTRODUCTION
Cytokines are soluble proteins that mediate the growth, homeo-
stasis, development, and effector functions of the immune
response, as well as provide critical crosstalk between adaptive
and innate immunity. Cytokines are keymediators of T cell-medi-
ated immunity and drive the differentiation of activated CD4+
T cells into the Th1, Th2, and Th17 T helper subtypes by dimer-
ization of cognate cytokine receptors and activation of Jak/STAT
signaling (Leonard, 1999). The four-helix bundle cytokines IL-4
and IL-13 have important roles in the differentiation and effector
functions of T helper cell type 2 (Th2)-polarized T cells, which are
necessary for the antiparasitic immune response (Wynn, 2003).
Largely produced by activated Th2 cells, IL-13 causes alterna-
tive activation of macrophages, induces class switching of
B cells to the IgE and IgG4 antibody isotypes, stimulates mast
cells and eosinophils, and can also induce changes in the respi-332 Structure 18, 332–342, March 10, 2010 ª2010 Elsevier Ltd All rigratory and vascular epithelium (Hershey, 2003). Dysregulation of
IL-13-mediated responses has been implicated in the pathology
of asthma and allergic disease (Barnes, 2002; Wills-Karp, 2004).
IL-13 signaling is initiated through heterodimerization of the
IL-13 receptor family members IL-13Ra1 and IL-4Ra in what is
termed the type II complex (Figures 1A and 1B) (Aman et al.,
1996; Hilton et al., 1996). IL-13 is first recruited by IL-13Ra1,
followed by binding of the binary IL-13/IL-13Ra1 complex to
IL-4Ra to form the ternary signaling complex (LaPorte et al.,
2008). Importantly, receptor dimerization is mediated by a
composite IL-13/IL-13Ra1 interface, and IL-13 alone has no
measurable affinity for IL-4Ra (Andrews et al., 2002). IL-4 can
also signal through a type II receptor heterodimer, but assembles
the receptor complex in the reverse order, whichmaypartially ex-
plain the different signaling potencies of IL-4 versus 13 (Junttila
et al., 2008; LaPorte et al., 2008). Upon dimerization, receptor-
associated Jak kinases recruit and activate STAT6 to induce
effector gene transcription (Kelly-Welch et al., 2003).
IL-13 also has the ability to form a second complex with its
high-affinity receptor, IL-13Ra2. Discovered contemporane-
ously with IL-13Ra1, IL-13Ra2 shares 21% sequence identity
with IL-13Ra1 (Caput et al., 1996) and, like IL-13Ra1, contains
an unusual top-mounted S-type Ig fold, followed by two fibro-
nectin type III-like domains and a WSXWS box that make up
the prototypical ‘‘cytokine-binding homology region’’ (CHR) (Do-
naldson et al., 1998) (Figure 1A). The biological role of IL-13Ra2
has been a matter of debate, due to its high affinity for IL-13 (re-
ported to be500 pM) and short intracellular domain (20 amino
acids) that lacks a canonical Box I/II Jak binding site and that
does not activate STAT6 upon cytokine binding (Caput et al.,
1996; Donaldson et al., 1998). IL-13Ra2 is upregulated during
certain types of infections (Chiaramonte et al., 2003; Mentink-
Kane et al., 2004; Morimoto et al., 2009) and is expressed on
multiple cell types outside of the hematopoietic system (Donald-
son et al., 1998). IL-13Ra2 has been found intracellularly, on the
cell surface, and as a shed-soluble receptor in mice (Daines and
Hershey, 2002; Daines et al., 2006), although it has not been
found as a soluble protein in human studies (O’Toole et al.,
2008). IL-13Ra2 knockoutmice exhibit a phenotype correspond-
ing to increased IL-13 production, including higher systemic
concentrations of IL-13 and increased IgE and IgG4 production
(Wood et al., 2003). This has led to a general consensus that
the primary role of IL-13Ra2 is as a decoy receptor and domi-
nant-negative regulator of IL-13 (Hershey, 2003; O’Toole et al.,hts reserved
Figure 1. The Overall Structure of the IL-13/
IL-13Ra2 Complex
(A) Schematic representation of the IL-13 receptor family.
S-Ig stands for s-type Ig domain. CHR stands for cytokine-
binding homology region. Disulfide bonds in the receptors
are represented by yellow lines.
(B) The structure of the IL-13/IL-13Ra1/IL-4Ra signaling
complex (PDB ID 3BPO).
(C and D) The structure of the IL-13/IL-13Ra2 complex.
Side (C) and face-on (D) views of IL-13/IL-13Ra2. IL-13
helices A–D are colored yellow and IL-13Ra2 domains
1–3 (D1–D3) are colored blue. The cytokine-receptor inter-
action sites II and III are highlighted in ovals. The single
N-acetylglucosamine sugar residue attached to Asn215
is colored orange and disulfide bonds are colored yellow.
Structure
The Structure of the IL-13/IL-13Ra2 Complex2008). However, recent studies suggest that IL-13Ra2 may also
have a role in signaling. It has been reported that IL-13 upregu-
lates TGF-b in fibroblasts in an IL-13Ra2-dependent manner
and that this upregulation is STAT6 independent yet requires
the intracellular domain of IL-13Ra2 (Fichtner-Feigl et al.,
2006). These data have been corroborated in vivo, with a study
showing that IL-13Ra2- and IL-13-dependent TGF-b production
are involved in promoting immune evasion of tumors in mice
(Fichtner-Feigl et al., 2008). While no dimeric signaling complex
containing IL-13Ra2 has been defined, these data add to the
potential roles of IL-13Ra2 in the immune response.
IL-13Ra2 has also attracted increasing interest for its potential
role in cancer. IL-13Ra2 has been found to be significantly upre-
gulated in a number of human cancers, including glioblastomas
and ovarian carcinomas (Kioi et al., 2006; Mintz et al., 2002). The
receptor has also attracted attention as a potential receptor for
targeted, tumor-specific therapeutics (Kahlon et al., 2004).
With a number of different strategies to inhibit IL-13 as well as
target IL-13Ra2 in therapeutic development, it is important to
understand the molecular basis for shared cytokine recognition
by the IL-13 receptor family. Molecular studies will also be
important to help understand whether IL-13Ra2 is solely a decoy
receptor or whether it also has a function as a signaling receptorStructure 18, 332–342, March 10through homo- or heterodimerization. Here, we
present the crystal structure of IL-13 in complex
with IL-13Ra2 and a comparative biophysical
analysis of the IL-13 interaction with IL-13Ra1
and IL-13Ra2 by alanine scanning and affinity
measurement. We discover that while the
IL-13 receptor-interacting residues are almost
completely conserved, IL-13Ra2 has evolved
an interlocking site II interface to bind IL-13
with an extraordinarily high affinity rarely seen
in nature, suggesting an important role for
this receptor in blocking IL-13 sensitivity in
IL-13Ra2-expressing cells.
RESULTS
The Structure of IL-13 Bound to IL-13Ra2
To express the IL-13/IL-13Ra2 complex for
crystallization, we co-infected insect HiFive
cells with recombinant baculoviruses encodingIL-13 and the cytokine binding domains (D1–D3) of IL-13Ra2.
As IL-13 and IL-13Ra2 are both heavily glycosylated (with four
predicted Asn-linked glycosylation sites on IL-13 and three on
IL-13Ra2), the insect cells were grown in the presence of kifu-
nensine to render Asn-linked glycans endoglycosidase-H
(Endo-H) sensitive. IL-13 and IL-13Ra2 viruses were then coin-
fected with Endo-H virus to cleave the kifunensine-sensitized
glycans in situ, leaving a single N-acetylglucosamine residue
attached to the Asn side chain (Lupardus and Garcia, 2008).
After purification, surface lysines were reductively methylated
(Walter et al., 2006) and the complex was purified by size exclu-
sion chromatography. Deglycosylated and methylated IL-13/IL-
13Ra2 complex behaved identically to the unmodified complex,
while crystal diffraction was improved from9 to 3.1 A˚ (Table 1).
The overall architecture of the IL-13/IL-13Ra2 complex is
similar to the structure of IL-13 in complex with IL-13Ra1
(Figures 1B–1D) (LaPorte et al., 2008). Preservation of the
general ‘‘two-site’’ binding mode, in which IL-13 appears to be
‘‘pinched’’ between the top and bottom domains of the receptor,
is not surprising given IL-13Ra1 and IL-13Ra2 evolved from
a common ancestor and have a similar domain structure (Arima
et al., 2005; Boulay et al., 2003). Compared to the more common
two-domain cytokine receptors, the cytokine-binding region of, 2010 ª2010 Elsevier Ltd All rights reserved 333
Table 1. Data Collection and Refinement Statistics for the IL-13/
IL-13Ra2 Complex
IL-13/IL-13Ra2 Native
Data collection
Space group I 2
Cell dimensions
a, b, c (A˚) 73.37, 86.57, 166.79
a, b, g () 90, 96.8, 90
Wavelength (A˚) 1.0
Resolution (A˚) 82.8–3.05 (3.21–3.05)
Rmerge 0.124 (0.581)
I/sI 7.6 (2.0)
Completeness (%) 100.0 (100.0)
Redundancy 3.8 (3.8)
Refinement
Resolution (A˚) 82.8–3.05
No. reflections (total/test) 18755/954
Rwork/Rfree 21.9/26.9
No. atoms
Protein 6027
Sugar 28
Calcium 2
Water 31
B factors
Protein 55.9
Sugar 75.5
Calcium 77.4
Water 38.7
Rmsd
Bond lengths (A˚) 0.012
Bond angles () 1.42
Highest resolution shell is in parentheses.
Structure
The Structure of the IL-13/IL-13Ra2 ComplexIL-13Ra2 consists of threedomains: N-terminal S-type Ig domain
(D1) and two fibronectin III-like domains (D2 and D3) that make
up the canonical CHR. The IL-13 receptor binding paradigm,
established by the interaction of IL-4 and IL-13 with IL-13Ra1,
is characterized by two binding sites, termed ‘‘site II’’ and ‘‘site
III’’ (LaPorte et al., 2008). Site II is the canonical ‘‘growth
hormone-like’’ interaction of the D2-D3 ‘‘elbow’’ region of the
CHR with the A and D helices of IL-13 (Figures 1C and 2B), while
site III is comprised of the A-B andC-D loops of the cytokine con-
tacting the D1 Ig-like domain through an extended anti-parallel
b sheet interaction (Figures 1C and 2A). Both of these interac-
tions are preserved in the IL-13/IL-13Ra2 complex, burying a
total of approximately 1840 A˚2 of surface area (1190 A˚2 and
650 A˚2 in site II and III, respectively).
The site II interface in the IL-13/IL-13Ra2 complex is formed by
an unusual splayed, ‘‘spider-like’’ arrangement of four side
chains on the D helix of IL-13 (K104, K105, F107, and R108)
(Figure 2B). Looking top-down onto the D helix, each of these
four residues is offset by 90, with three of the four (K104,
F107, and R108) inserting into depressions created by the
D2-D3 CHR loops on IL-13Ra2. K104 fits in a groove created334 Structure 18, 332–342, March 10, 2010 ª2010 Elsevier Ltd All rigby the D3 FG loop of IL-13Ra2, while R108 inserts into a canyon
created by the BC loop of D3 and the AB and EF loops of D2.
K104 and R108 also form polar bonds to the receptor at the
periphery of the interface, with K104 forming a salt bridge with
D318 and R108 participating in a hydrogen bond with the back-
bone carbonyl of P266. F107 occupies a pocket lined by the IL-
13Ra2 residues Y315, the BC-FG loop disulfide (C269-C316),
and R268, which also forms two hydrogen bonds with the
peptide carbonyls of F107 and R108 in IL-13. The A helix contrib-
utes R11, I14, and E15 to the interface, with R11 and E15 forming
a pocket for and hydrogen bonding with the IL-13Ra2 FG loop
residue Y315.
The defining feature of the site III interface is the extension of
the antiparallel b sheet of the IL-13Ra2 D1 Ig domain by two
strands formed by the AB and CD loops of IL-13 (Figure 2A).
The IL-13Ra2 interface is dominated by the backbone of the
D1 c’ b strand along with the side chains of residues T83, I84,
I85, and T86. These opposing side chains form a flat, nonpolar
interface complementary to the IL-13 site III epitope, which is
formed by the CD loop strand and a hydrophobic patch gener-
ated by M33, W35, and the methylene chain of K89. Each end
of the c’ strand of IL-13Ra2 is ‘‘capped’’ with lysines (K82 and
K89). Overall, the site III interaction is primarily driven by the
backbone b sheet hydrogen bonding with nonpolar van der
Waals interactions between the side chains on each side.
IL-13 Binding Energetics
To biophysically characterize the interaction between IL-13 and
IL-13Ra2 and compare the binding energetics to that of the
IL-13/IL-13Ra1 complex, we used two methods to measure
the affinity of the IL-13/IL-13Ra2 complex: thermodynamic anal-
ysis by isothermal titration calorimetry (ITC) and kinetic analysis
by surface plasmon resonance (SPR). We performed ITC as
described previously (LaPorte et al., 2008), using fully glycosy-
lated IL-13 and soluble extracellular domains for IL-13Ra1 and
IL-13Ra2. When we measured the thermodynamics of IL-13
binding to IL-13Ra2 by ITC, we found the reaction to be strongly
exothermic (DH = 20.0 kcal/mol), but the high affinity of the
interaction produced a steep titration transition that could not
be accurately fit to determine KD (Figure 3A). To accurately
determine the dissociation constant, we performed displace-
ment ITC, a method developed to reduce the apparent KD of
an interaction by pre-complexing one of the binding partners
with a ligand of lower affinity (Sigurskjold, 2000). We were able
to take advantage of the relatively lower affinity of IL-13Ra1 for
IL-13 (Figure 3B) and use it as a competitor for IL-13Ra2 binding.
By this method, we were able to accurately fit the titration tran-
sition and measure a dissociation constant of 4.7 pM for the
IL-13/IL-13Ra2 interaction (Figure 3C). As measured by ITC,
IL-13Ra2 therefore has over 5000-fold higher affinity for IL-13
than IL-13Ra1. This interaction is enthalpically driven and entro-
pically unfavorable. Although one cannot unambiguously assign
energetics simply by inspection of structure, the ITC results
suggest that the interaction between IL-13 and IL-13Ra2 is, on
balance, driven primarily by formation of polar bonds, which
tend to have strong exothermic signatures, and to a lesser extent
desolvation, which tends to be entropically favorable, although
the site II interface does contain several clearly hydrophobic
interactions.hts reserved
Figure 2. The Interactions of IL-13Ra2 with IL-13
The overall structure to the left is a ribbon depiction of IL-13 bound to a molecular surface of IL-13Ra2.
(A) View of the ‘‘site III’’ interface showing the backbone b sheet interactions between the c’ strand of IL-13Ra2 D1 and the CD loop strand of IL-13.
(B) View of the ‘‘site II’’ interface, showing the interactions between the D2 and D3 loops of IL-13Ra2 and the A and D helices of IL-13. Interacting residues are
shown as sticks and polar interactions are drawn as dashed red lines.
Structure
The Structure of the IL-13/IL-13Ra2 ComplexWe next measured the kinetics of binding for both the IL-13/
IL-13Ra1 and IL-13/IL-13Ra2 interactions. C-terminally biotiny-
lated IL-13Ra1 or IL-13Ra2 were immobilized on a streptavidin
SPR surface, with a range of IL-13 concentrations passed over
the surface to measure rates of association and dissociation.
We found the affinity between IL-13 and IL-13Ra1 to be
1.7 nM by SPR (Figure 3D), consistent with previously reported
values (Andrews et al., 2002), albeit with 10-fold higher affinity
than observed via ITC. We then attempted to determine the
affinity between IL-13 and IL-13Ra2 using SPR and found
the complex had an exceptionally slow dissociation rate.
Even when allowed to dissociate for 180 min (compared to
1 min for IL-13/IL-13Ra1 dissociation measurements), there
was essentially no dissociation of IL-13 from IL-13Ra2
observed (Figure 3E). Our measurements indicate a dissocia-
tion rate slower than 2 3 106 s1 and an interaction half-lifeStructure 18, 3of several days (t1/2 = ln2/koff). While an exact KD cannot be
determined with high confidence due to limitations in accu-
rately measuring the complex dissociation, these kinetic read-
ings indicate IL-13Ra2 has sub-100 fM affinity for IL-13 by
SPR. These results indicate the IL-13/IL-13Ra2 interaction is
among the highest affinity protein-protein complexes reported
in the literature.
Comparison of the IL-13/Receptor Complexes
These extraordinary differences in affinity led us to carefully
compare our structure to the structure of IL-13 in complex with
IL-13Ra1 (PDB ID 3BPO) (LaPorte et al., 2008) to determine
themolecular basis for the greater than 20,000-fold affinity differ-
ential observed between the complexes. Overlay of the IL-13
molecules indicates that the structure of the cytokine is nearly
unchanged upon binding to its receptors (see Figure S2 available32–342, March 10, 2010 ª2010 Elsevier Ltd All rights reserved 335
Figure 3. Biophysical Characterization of the IL-13 Interaction with IL-13Ra1 and IL-13Ra2
(A–C) Thermodynamic measurements of binding performed by ITC. Parameters measured for binding of IL-13 to IL-13Ra2 (A), IL-13 to IL-13Ra1 (B), and
displacement of IL-13Ra1 from IL-13 by IL-13Ra2 (C) are summarized in the tables below each binding isotherm. Only DH could be calculated from the
IL-13/IL-13Ra2 titration; the data could not be fit for KD due to the steepness of the curve.
(D and E) SPR measurement of binding kinetics for the IL-13/IL-13Ra1 and IL-13/IL-13Ra2 interactions.
Structure
The Structure of the IL-13/IL-13Ra2 Complexonline), with a Ca backbone root mean square deviation of
1.1 A˚. Clearly, the cross-reactivity of IL-13 for IL-13Ra1 and
IL-13Ra2 is not mediated by significant changes in the contact
residues or side chain positions on the A and D helices of IL-13
(Figure S2). Comparison of rotamer positions of IL-13 for sites
II and III show surprisingly few differences between the336 Structure 18, 332–342, March 10, 2010 ª2010 Elsevier Ltd All rigIL-13Ra1 and IL-13Ra2 complexes, with one major exception
being the site II D helix residue R108. Instead, the difference in
affinity seems to be almost entirely mediated by sequence and
structural differences of the contact surfaces presented by the
two receptors (Figures 4A–4F) and, in particular, the site II inter-
face (Figures 4C–4F). Perhaps most prominently, in site II, the D2hts reserved
Figure 4. Comparison of the Site II and Site III Interfaces for IL-13 in
Complex with IL-13Ra1 and IL-13Ra2
To make comparisons between the two IL-13/receptor complexes, the IL-13
molecules were structurally superimposed.
(A–D) Comparison of residues that comprise the site III and site II interfaces for
IL-13Ra2 (A and C, in blue) and IL-13Ra1 (B and D, in green). Cytokine-inter-
acting residues are shown as sticks.
(E and F) ‘‘Projection’’ view of IL-13 helices A and D depicted as ribbons and
sticks interacting with semi-transparent molecular surfaces of IL-13Ra2 (E)
and IL-13Ra1 (F). Interacting residues are shown as sticks, with the key hot-
spot residues I14, K104, and F107 colored pink.
Structure
The Structure of the IL-13/IL-13Ra2 Complex
Structure 18, 3EF loop of IL-13Ra2 protrudes toward the D helix of IL-13, and
Y207 at the tip of this loopmakes a number of important contacts
with L101, K105, and R108 of IL-13 (Figures 4C and 4E). The D2
EF loop is disordered in the structure of IL-13/IL-13Ra1
(Figure 4D), and the absence of cytokine contacts leaves a large
empty space between IL-13 helix D and IL-13Ra1 (Figure 4F);
this empty space is occupied by the D2 EF loop in the
IL-13Ra2 complex (compare Figure 4E to 4F). Due to the usage
of the EF loop by IL-13Ra2, comparison of the site II interfaces
shows a significant increase in buried surface area (1190 A˚2
versus 880 A˚2) compared to IL-13Ra1 (Figure 5). In fact, the
IL-13Ra2 Y207 contact with K105 of IL-13 is distinct in the
IL-13Ra2 complex (Figure 5) and denotes a clear site of speci-
ficity between the two complexes that we interrogated by muta-
genesis (discussed below).
The differences between the site III interfaces are less striking
(Figures 4A and 4B), with 660 A˚2 and 650 A˚2 buried for IL-13Ra1
and IL-13Ra2 (Figure 5), respectively, and the interfaces domi-
nated by backbone b sheet hydrogen bonds and nonpolar van
der Waals interactions. There is little sequence conservation
between the IL-13-interacting residues in IL-13Ra1 and
IL-13Ra2 (Figure 4A, inset), suggesting that, as for site II, each
complex has evolved a highly distinct set of receptor-ligand
contacts.
Alanine-Scanning Mutagenesis of the IL-13 Interface
Our discovery that IL-13 uses primarily the same residues to
bind IL-13Ra1 and IL-13Ra2 with dramatically different affinities
led us to investigate the relative energetic contributions that
each side chain makes to the overall affinity of each complex.
We identified the fifteen residues in IL-13 that made significant
side chain interactions in either or both of the receptor-binding
interfaces (Table S1 and Figure S3) and created a panel of
alanine point mutants for SPR affinity measurements against
IL-13Ra1 and IL-13Ra2. Due to the extremely slow dissociation
rate between IL-13 and IL-13Ra2, we first performed a single-
concentration binding screen by flowing 3 nM of each IL-13
mutant over immobilized IL-13Ra2. While there was some vari-
ation in observed association rate for several of the IL-13
mutants, only four mutants showed any appreciable dissocia-
tion within the 10 min window used for the screen: I14A,
K104A, K105A, and F107A (Figure S4). We performed complete
kinetic analysis of these four mutants and found the KD values
for these mutants to be 1 pM, 9 pM, 70 pM, and 289 pM
for K105A, I14A, F107A, and K104A, respectively (Figure S4;
Table 2). Each mutant showed an approximately 10-fold
decrease in association rate (108 M1s1 to 107 M1s1),
but a 10- to 10,000-fold increase in the dissociation rate
(Table 2). ITC measurements for IL-13 K104A and F107A binding
to IL-13Ra2 were also performed, and these interactions were
found to have KD values of 2.8 and 1.3 nM, respectively
(Figure S6). These results are between two and three orders of
magnitude lower affinity than the wild-type IL-13 binding to
IL-13Ra2 by ITC (4.7 pM), corresponding to the change in affinity
seen in our SPR measurements.
We nextmade affinity measurements via SPR for IL-13 binding
to IL-13Ra1 to identify the energetically important interacting
residues for this complex. We found that unlike IL-13Ra2, muta-
tion of both site II and site III residues could disrupt the affinity of32–342, March 10, 2010 ª2010 Elsevier Ltd All rights reserved 337
Figure 5. Shared and Distinct Contact
Surfaces in the IL-13/IL-13Ra2 and IL-13/
IL-13Ra1 Interfaces
Surface representation of IL-13 (middle panel),
with residues interacting with IL-13Ra2 (pink),
IL-13Ra1 (teal), or both receptors (yellow)
highlighted. The IL-13-interacting surfaces of
IL-13Ra2 and IL-13Ra1 are highlighted in pink
and yellow, respectively (left and right panels).
Structure
The Structure of the IL-13/IL-13Ra2 ComplexIL-13Ra1 for IL-13. In site III of IL-13, mutation of residues K89,
I90, and E91 each decrease affinity for IL-13Ra1 by 10-fold,
while M33A has a more significant effect (50-fold decrease)
and D87A and T88A had no effect (Figure S5; Table 2). In
contrast, none of these IL-13 point mutants appreciably disrup-
ted IL-13Ra2 binding. Each of these side chains contribute
significant surface area to both site III binding interfaces
(Figure 5; Figure S3), so it appears that the IL-13/IL-13Ra2 site
III interface is more tolerant to point mutations, with the high
affinity of the site II interface possibly able to compensate for
site III disruption.
The site II mutants that most severely disrupt IL-13Ra2
binding (I14A, K104A, and F107A) also significantly weaken
the IL-13/IL-13Ra1 interaction, with binding being reduced
200-fold for I14A and K104A (Table 2; Figure S4). IL-13
F107A disrupts affinity for IL-13Ra1 by at least 50-fold; the
actual extent of disruption is likely larger, as the IL-13 F107A
mutant was poorly behaved at concentrations higher than
1 mM, which caused the SPR sensorgrams to show severe
perturbations at equilibrium and not approach the theoretical
Rmax for the surface (Figure S4). In addition to those shared resi-
dues, each IL-13 complex also has distinct IL-13 D helix resi-
dues that disrupt binding upon mutation to alanine. In the
IL-13/IL-13Ra2 complex, mutation of IL-13 K105 to alanine
reduces binding over 10-fold (Table 2), likely due to contacts
the K105 side chain makes with Y207 in the D2 E-F loop
(Figures 4C and 4E). In the IL-13/IL-13Ra1 complex, IL-13
K105 does not contact the receptor due to the lack of involve-
ment of the IL-13Ra1 EF loop in IL-13 binding; instead, IL-13
R108 packs into the space on IL-13Ra1 occupied by K105
and the D2 E-F loop in the IL-13Ra2 structure (Figures 4E and
4F). Predictably, mutation of K105 to alanine does not affect
IL-13Ra1 binding due to its lack of contact in the structure,
while changing R108 to alanine reduces affinity for IL-13Ra1
by 100-fold (Table 2). Interestingly, even though R108 appears338 Structure 18, 332–342, March 10, 2010 ª2010 Elsevier Ltd All rights reservedto make extensive contacts with
IL-13Ra2 (Figure 4E), mutation of this
residue to alanine has no appreciable
effect on complex affinity. Therefore,
while there are slight differences in
IL-13 residues energetically important
for IL-13Ra1 and IL-13Ra2 complex
formation that could serve as targets to
produce IL-13 variants with more or less
selectivity for IL-13Ra1 versus IL-13Ra2
(such as K105), the cluster of residues
I14, K104, and F107 compose a mutuallyshared ‘‘hotspot’’ surface and functional epitope essential for
binding of IL-13 to both receptors.
Specific versus Degenerate Binding in the IL-13
Receptor Family
Prior studies have shown that while IL-13 binds to both IL-13Ra1
and IL-13Ra2, IL-4 can only bind IL-13Ra1 after first forming
a complex with IL-4Ra and has no apparent affinity for IL-
13Ra2 (Andrews et al., 2002, 2006). An important question that
we can now address is how IL-13Ra2 has evolved high affinity
for IL-13 without also gaining additional affinity for IL-4. An align-
ment of the A and D helices of IL-4 bound to IL-13Ra1, IL-13
bound to IL-13Ra1, and IL-13 bound to IL-13Ra2 shows that
the IL-13 hotspot residues I14, K104, and F107 correspond to
IL-4 residues I11, R121, and Y124, respectively (Figure 6). This
high level of conservation, including similar rotamer conforma-
tions, indicates the core IL-13 receptor binding hotspot on IL-4
and IL-13 is preserved among the complexes. Importantly,
a number of peripheral IL-13 amino acids that participate in the
IL-13Ra2 complex but neither of the IL-13Ra1 complexes are
quite divergent, including two charge reversals (K105/E122
and E15/K12 on IL-13 and IL-4, respectively) (Figure 6).
This leads us to conclude that IL-13Ra2 has evolved to specifi-
cally interact with IL-13 via increased shape complementarity
and additional peripheral contacts with the cytokine, while
IL-13Ra1 has remained promiscuous by primarily interacting
with the shared core of IL-4/IL-13 hotspot residues and mini-
mizing peripheral contacts.
DISCUSSION
IL-13Ra2 is a high affinity IL-13-specific receptor thought to
function as a ‘‘decoy’’ and regulator of IL-13 signaling. Here we
report the crystal structure of IL-13 in complex with IL-13Ra2,
which reveals the molecular basis for the extraordinary affinity
Table 2. Summary of Kinetic and Thermodynamic Binding Measurements for IL-13 Mutants Binding to IL-13Ra1 and IL-13Ra2
SPR Kinetics/Equilibrium Affinity
IL-13 Mutant
IL-13Ra1 Immobilized IL-13Ra2 Immobilized
kon (M
1s1) koff (s
1) KD (M
1) kon (M
1s1) koff (s
1) KD (M
1)
IL-13WT 2.35 3 106 3.97 3 103 1.69 3 109 1.22 3 108 1.93 3 106 1.58 3 1014
IL-13 R11A 1.87 3 106 4.87 3 103 2.60 3 109
IL-13 I14A 3.17 3 107 1.79 3 107 1.52 3 104 8.47 3 1012
IL-13 E15A 2.82 3 106 4.45 3 103 1.58 3 109
IL-13 V18A 3.26 3 106 4.43 3 103 1.36 3 109
IL-13 M33A 8.65 3 108
IL-13 D87A 2.74 3 106 7.51 3 103 2.74 3 109
IL-13 T88A 2.80 3 106 4.88 3 103 1.75 3 109
IL-13 K89A 1.28 3 108
IL-13 I90A 1.70 3 108
IL-13 E91A 1.35 3 108
IL-13 L101A 3.53 3 106 4.63 3 103 1.31 3 109
IL-13 K104A 3.93 3 107 9.64 3 106 2.71 3 103 2.89 3 1010
IL-13 K105A 1.31 3 106 7.71 3 103 5.89 3 109 9.16 3 106 1.06 3 105 1.16 3 1012
IL-13 F107A >1.0 3 107a 1.15 3 107 9.45 3 104 8.91 3 1011
IL-13 R108A 2.11 3 107
ITC Thermodynamics
Titrand Titrant DH
(kcal/mol)
DS
(cal/mol*K)
DG
(kcal/mol)
KD (M
1) n
IL-13 IL-13Ra1 11.4 2.8 10.5 2.5 3 108 0.937
IL-13 IL-13Ra2 20.0 ND ND ND 0.980
IL-13/
IL-13Ra1
IL-R13a2 20.1 14.5 15.7 4.7 3 1012 0.943
IL-13 K104A IL-R13a2 20.4 28.2 11.9 2.78 3 109 0.884
IL-13 F107A IL-R13a2 17.1 15.7 12.3 1.27 3 109 0.949
aAccurate KD could not be determined due to non-specific binding of IL-13F107A to the SPR control channel at concentrations >1mM.
Structure
The Structure of the IL-13/IL-13Ra2 Complexof the receptor for IL-13. An alanine scan of the IL-13 interface to
determine the amino acids most important for binding to
IL-13Ra1 and IL-13Ra2 indicates that both receptors use
a central set of site II hotspot residues for binding to IL-13. Yet
in contrast to IL-13Ra1, IL-13Ra2 makes a number of peripheral
interface contacts to gain specificity and a four orders of magni-
tude increase in binding affinity.
Our structure and the accompanying biophysical analysis of
the IL-13/IL-13Ra2 complex raise several important questions
related to the in vivo function of IL-13Ra2. The femtomolar
affinity of IL-13Ra2 for IL-13 is unprecedented in cytokine/
receptor interactions and ranks among the highest affinity non-
covalent protein-protein interactions as yet identified. Why is
such tight binding necessary for IL-13 regulation? It has been
previously suggested that IL-13Ra2 functions at least in part as
a decoy receptor, reducing levels of IL-13 in the cellular microen-
vironment and downregulating IL-13 signaling on cells express-
ing the receptor. This has been suggested by experiments in
which downregulation of IL-13 signaling after parasitic infection
was dependent on IL-13Ra2 (Chiaramonte et al., 2003; Men-
tink-Kane et al., 2004) and in which an IL-13 overexpression
phenotype is seen in an IL-13Ra2 mouse knockout model
(Wood et al., 2003). A number of decoy receptors involved in
cytokine regulation have been characterized, including IL-1Structure 18, 3receptor II (IL-1RII), which neutralizes the proinflammatory cyto-
kine IL-1 (Dinarello, 2009), and the DcR family of receptors
(DcR1-3), which bind to the apoptosis-inducing TNF-related
molecules TRAIL and FasL (Ashkenazi andDixit, 1999). Addition-
ally, a number of viruses use decoy receptors to modulate the
activities of the TNF, IL-1, and IFN families of cytokines (Alcami,
2003). From our affinity measurements IL-13Ra2 has at least
a 5000-fold greater affinity for IL-13 than IL-13Ra1, so any
expression of IL-13Ra2 on the surface of a cell would cause
a substantial downregulation of IL-13 signaling. It is therefore
very likely that a significant role for IL-13Ra2 in vivo is as a decoy
receptor and brake on IL-13 signaling.
The high affinity of IL-13Ra2 for IL-13 would also seem to
necessitate tight regulation of IL-13Ra2 expression and/or local-
ization, due to the significant effect even small amounts of
IL-13Ra2 could have on IL-13 signaling. It has been shown in
U937 cells that IL-13Ra2 is only expressed at low levels on the
cell surface but is rapidly upregulated in response to IFN-g
(Daines and Hershey, 2002). Additionally, strong IL-13Ra2 stain-
ing is seen in intracellular compartments (Daines and Hershey,
2002), suggesting the functional receptormay be held in intracel-
lular stores and only trafficked to the cell surface in response to
very specific cytokine-mediated signals. IL-13Ra2 is also inter-
nalized quickly upon IL-13 binding (Kawakami et al., 2001),32–342, March 10, 2010 ª2010 Elsevier Ltd All rights reserved 339
Figure 6. An IL-4/IL-13 Hotspot Mediates binding to the IL-13
Receptor Family
The A and D helices of IL-13 molecules from our IL-13/IL-13Ra2 complex and
the IL-13/IL-13Ra1 complex (PDB 3BPO) were aligned along with the A and D
helices of IL-4 from the IL-4/IL-13Ra1 complex (PDB 3BPN). Side chains inter-
acting with IL-13Ra1 or IL-13Ra2 are shown as stick models. The IL-13
receptor binding hotspot consisting of the IL-13/IL-4 residues I14/I11, K104/
R121, and F107/Y124 is highlighted.
Structure
The Structure of the IL-13/IL-13Ra2 Complexsuggesting that both the surface expression level and the
amount of free receptor are kept under stringent control.
With regards to signaling, it has been shown that IL-13Ra2
does not signal through a canonical Jak/STAT signaling pathway
due a lack of interactionwith IL-4Ra aswell as a short intracellular
domain lacking Jak interaction motifs (Andrews et al., 2006). In
the IL-13 type 2 signaling complex, the binary IL-13/IL-13Ra1
complex interacts with IL-4Ra through a composite cytokine-
receptor and receptor-receptor binding surface (LaPorte et al.,
2008). Comparison of the receptor-receptor dimerization inter-
face of IL-13Ra1 with the same region on IL-13Ra2 shows signif-
icant structural differences that likely preclude an IL-4Ra/
IL-13Ra2 interaction. IL-13Ra1 residues F297 and P300 (shown
to be conserved also in common g chain) (LaPorte et al., 2008)
correspond to tyrosine (Y293) and alanine (A296) in IL-13Ra2,
with Y293 in particular pushed out into the interface and likely
sterically restricting an interaction with IL-4Ra (Figure S7). Func-
tional studies, SPR analysis, and native gel electrophoresis have
all demonstrated no measurable affinity between IL-4Ra and the
IL-13/IL-13Ra2 complex (Andrews et al., 2002, 2006; data not
shown). The unusually high affinity of IL-13Ra2 for IL-13 would
also seem to be mutually exclusive with canonical Jak/STAT
signaling, due to the need for ‘‘tuneability,’’ or a scaling up and
down in signaling in response to differing levels of ligand.
Alternate STAT-independent signaling modalities, as proposed
previously (Fichtner-Feigl et al., 2006), may rely on undescribed
mechanisms that do not require ‘‘tuneable’’ affinity.340 Structure 18, 332–342, March 10, 2010 ª2010 Elsevier Ltd All rigEXPERIMENTAL PROCEDURES
Protein Expression and Purification
Human IL-13 (amino acids 21–132) and the IL-13Ra2 ectodomain (amino acids
29–331) were cloned into the pAcGP67-A vector (BD Biosciences) in frame
with an N-terminal gp67 signal sequence and C-terminal hexahistidine tag
and produced using the baculovirus expression system. Baculovirus stocks
were prepared by transfection and amplification in Spodoptera frugiperda
(Sf9) cells grown in SF900II media (Invitrogen), and protein expression was
carried out in suspension Trichoplusia ni (HiFive) cells grown in InsectXpress
media (Lonza).
For biophysical experiments, IL-13, IL-13Ra1 (LaPorte et al., 2008), and
IL-13Ra2 were individually expressed and captured from HiFive supernatants
after 48 hr by nickel agarose (QIAGEN), concentrated and purified by size
exclusion chromatography on a Superdex 200 column (GE Healthcare), equil-
ibrated in 5 mM HEPES (pH 7.0) and 150 mM NaCl (HEPES-buffered saline).
For crystallization, glycan-minimized IL-13/IL-13Ra2 complex was generated
by coinfection of kifunensine-treated HiFive cells with IL-13, IL-13Ra2, and
Endo-H viruses. After nickel purification, the complex was treated overnight
with carboxypeptidase-A, diluted to 1 mg/ml, and modified by reductive
methylation (Walter et al., 2006). The Endo-H trimmed andmethylated complex
was then concentrated and purified by size exclusion in HEPES-buffered
saline. Peak fractions were pooled and concentrated to 10–12 mg/ml for
crystallization.
Crystallization and Data Collection
Initial crystallization trials yielded needle-like crystals from the PACT crystalli-
zation screen (Molecular Dimensions) using the sitting drop method at 25C.
Diffraction-quality crystals were ultimately grown in sitting drops at 25C by
mixing 0.1 ml protein [10 mg/ml in 5 mM HEPES-NaOH (pH 7.0) and 150 mM
NaCl] with an equal volume of 100 mM MES (pH 6.0), 200 mM CaCl2, 20%
PEG-6000, and 4% v/v polypropylene glycol. Crystals grew to a maximum
size of 100 3 100 3 100 mM in 2–3 weeks. Crystals were flash frozen in liquid
nitrogen using mother liquor containing 25% glycerol as a cryoprotectant. A
3.1 A˚ data set was collected under cryo-cooled conditions at beamline 9-2
at the Stanford Synchotron Radiation Laboratory. Diffraction data were pro-
cessed using MOSFLM (Leslie, 1992) and SCALA (Potterton et al., 2003).
Data processing statistics can be found in Table 1.
Structure Determination and Refinement
Initial phase information was obtained by molecular replacement with the
programPHASER (McCoy et al., 2007) using the coordinates of IL-13, followed
by placement of the individual domains of IL-13Ra1 from the IL-13/IL-4Ra/
IL-13Ra1 ternary complex structure (PDB ID 3BPO) (LaPorte et al., 2008). After
the IL-13Ra1 domains were placed, the sequence was converted to poly-
alanine and iterative rounds of simulated annealing refinement with CNS
(Brunger, 2007) and model adjustment with COOT (Emsley and Cowtan,
2004) were carried out to build the IL-13Ra2 model. Once all amino acid
changes and register problems were resolved, final rounds of positional,
ADP, and TLS refinement were carried out using the PHENIX package (Adams
et al., 2002) resulting in final Rwork and Rfree values of 21.9% and 26.9%,
respectively. Ramachandran analysis by MolProbity (http://molprobity.
biochem.duke.edu) (Davis et al., 2007) indicates 90.4% of residues reside in
the most favorable regions, with none in the disallowed regions. Contact
maps and buried surface area values were calculated using the Protein Inter-
faces, Surfaces, and Assemblies (PISA) server (http://www.ebi.ac.uk/msd-srv/
prot_int/pistart.html) (Krissinel and Henrick, 2007). Overlay of coordinates was
carried out using SUPERPOSE from the CCP4 suite (Potterton et al., 2003).
All structural figures were prepared using PyMOL (http://www.pymol.org)
(DeLano, 2002).
The final model consists of two IL-13/IL-13Ra2 complexes in the asym-
metric unit, with IL-13 chain A and IL-13Ra2 chain C making up one complex
and IL-13 chain B and IL-13Ra2 chain D making up the second copy. Several
loops in between strands of the Ig-like domains of the IL-13Ra2 molecules
were modeled as alanine or unmodeled due to a lack of electron density.
A number of lysines throughout the structure were modeled as dimethyl-lysine
when additional electron density was found around the terminal amine, and
one calcium atom bound to each IL-13Ra2 was modeled into the structure,hts reserved
Structure
The Structure of the IL-13/IL-13Ra2 Complexcoordinated by Asp93 away from the IL-13/IL-13Ra2 binding interfaces. IL-
13Ra2 chains C and D each have a single N-acetylglucosamine moiety
attached to Asp215 in the model. The amino acid numbering scheme in the
PDB file corresponds to the mature, signal peptide-cleaved chain of IL-13
and the non-cleaved sequence of IL-13Ra2 to facilitate comparison with the
IL-13/IL-13Ra1 complex (PDB 3BPO). Chains B (IL-13) and D (IL-13Ra2)
were used for all figures in the paper.
Surface Plasmon Resonance
SPR experiments were conducted on a Biacore T100 instrument. IL-13 and all
alanine mutants were expressed fully glycoslylated in HiFive cells and purified
via gel filtration, and all mutants behaved identically to wild-type IL-13.
IL-13Ra1 and IL-13Ra2 contained a C-terminal biotinylation peptide (LHHIL-
DAQKMVWNHR) and were expressed and purified, followed by biotinylation
in vitro with GST-BirA ligase according to established protocols (O’Callaghan
et al., 1999). After the biotinylation reaction was complete, receptors were re-
purified by size exclusion chromatography to remove excess biotin. Protein
concentrations were quantified by UV spectroscopy at 280 nm using a Nano-
drop2000 spectrometer (Thermo Scientific), and readings were taken three
times and averaged to determine protein concentration. All data was analyzed
using the Biacore T100 evaluation software version 2.0 with a 1:1 Langmuir
binding model.
Experiments were either conducted using a Biacore SA sensor chip or a Bia-
core Biotin CAPture Kit (GE Healthcare). Biotinylated receptors were captured
at a low density (200–300 RU) and kinetic runs were conducted at 50 ml/min. An
unrelated biotinylated protein was immobilized as a reference surface for the
SA sensor chip with matching RU to the experimental surface. For the SA
sensor chip, IL-13Ra1 was regenerated using 10 mM sodium acetate
(pH 4.0) and 250mMNaCl and IL-13Ra2was regenerated using 10mMglycine
(pH 2.5) and 125 mM NaCl.
All measurements were made using 3-fold serial dilution of IL-13 and IL-13
mutants as indicated. IL-13/IL-13Ra1 kinetics data was determined using
160 s association and 60 s dissociation. IL-13/IL-13Ra2 kinetics data was
determined using 300 s association and 10,800 s (180 min) dissociation. The
initial single-concentration binding screen to identify IL-13 mutants with
altered binding to IL-13Ra2 used 3 nM IL-13, with 120 s association and
360 s dissociation. Kinetic experiments for IL-13 mutants binding to
IL-13Ra1 were conducted identically to wild-type IL-13Ra1 measurements.
When the data could not be fit for kinetics, equilibrium data was determined
at 30 ml/min flow rate with 270 s association and 60 s dissociation. Kinetic
data for IL-13 mutants binding to IL-13Ra2 was conducted with 300 s associ-
ation and 1800 s (30 min) dissociation time for IL-13 I14A, K104A, and F107A,
with 3600 s (60 min) dissociation for IL-13 K105A.
Isothermal Titration Calorimetry
Calorimetric titrations were carried out on a VP-ITC calorimeter (MicroCal) at
30C. Fully glycosylated proteins were expressed in HiFive cells and gel puri-
fied in HEPES-buffered saline (5 mM HEPES-NaOH and 150 mM NaCl).
Proteins were quantified by UV spectroscopy as described above. Each
experiment was conducted with 30 injections of 10 ml each of titrant. Injections
were conducted over 20.5 s with 360 s between injections to allow the reaction
to come to equilibrium. For IL-13/IL-13Ra1 measurements, IL-13Ra1 was the
titrant at a concentration of 40 mM and IL-13 was the titrand at 5 mM. For the
wild-type IL-13/IL-13Ra2 measurements, IL-13Ra2 was the titrant at 8 mM
and IL-13 was the titrand at 1 mM. For measurement of the IL-13 mutants
K104A and F107A with IL-13Ra2, IL-13Ra2 was the titrant in the syringe at
a concentration of 40 mM and IL-13 was the titrand at 5 mM. For displacement
ITC measurements (Sigurskjold, 2000), 5 mM IL-13 pre-incubated for 30 min
with 100 mM IL-13Ra1 was used as the titrand and 40 mM IL-13Ra2 was
used as the titrant. All data processing was performed using Origin 7.0. Stoi-
chiometry measurements via ITC were all n = 0.88–1.0, indicating 1:1 molec-
ular interactions.ACCESSION NUMBERS
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